135 related articles for article (PubMed ID: 14514729)
1. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.
Bao L; Zhou J; Holers VM; Quigg RJ
J Am Soc Nephrol; 2003 Oct; 14(10):2516-25. PubMed ID: 14514729
[TBL] [Abstract][Full Text] [Related]
2. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.
Bao L; Haas M; Kraus DM; Hack BK; Rakstang JK; Holers VM; Quigg RJ
J Am Soc Nephrol; 2003 Mar; 14(3):670-9. PubMed ID: 12595503
[TBL] [Abstract][Full Text] [Related]
3. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S
J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863
[TBL] [Abstract][Full Text] [Related]
4. Alteration in kidney glucose and amino acids are implicated in renal pathology in MRL/lpr mice.
Alexander JJ; Zwingmann C; Jacob A; Quigg R
Biochim Biophys Acta; 2007 Oct; 1772(10):1143-9. PubMed ID: 17942282
[TBL] [Abstract][Full Text] [Related]
5. Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis.
Alexander JJ; Jacob A; Bao L; Macdonald RL; Quigg RJ
J Immunol; 2005 Dec; 175(12):8312-9. PubMed ID: 16339572
[TBL] [Abstract][Full Text] [Related]
6. Absence of functional alternative complement pathway alleviates lupus cerebritis.
Alexander JJ; Jacob A; Vezina P; Sekine H; Gilkeson GS; Quigg RJ
Eur J Immunol; 2007 Jun; 37(6):1691-701. PubMed ID: 17523212
[TBL] [Abstract][Full Text] [Related]
7. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.
Bao L; Haas M; Boackle SA; Kraus DM; Cunningham PN; Park P; Alexander JJ; Anderson RK; Culhane K; Holers VM; Quigg RJ
J Immunol; 2002 Apr; 168(7):3601-7. PubMed ID: 11907125
[TBL] [Abstract][Full Text] [Related]
8. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
Sekine H; Reilly CM; Molano ID; Garnier G; Circolo A; Ruiz P; Holers VM; Boackle SA; Gilkeson GS
J Immunol; 2001 May; 166(10):6444-51. PubMed ID: 11342671
[TBL] [Abstract][Full Text] [Related]
9. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis.
Alexander JJ; Bao L; Jacob A; Kraus DM; Holers VM; Quigg RJ
Biochim Biophys Acta; 2003 Nov; 1639(3):169-76. PubMed ID: 14636948
[TBL] [Abstract][Full Text] [Related]
10. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
Shi Y; Yao W; Sun L; Li G; Liu H; Ding P; Hu W; Xu H
BMC Nephrol; 2019 Nov; 20(1):424. PubMed ID: 31752725
[TBL] [Abstract][Full Text] [Related]
11. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
Watanabe H; Garnier G; Circolo A; Wetsel RA; Ruiz P; Holers VM; Boackle SA; Colten HR; Gilkeson GS
J Immunol; 2000 Jan; 164(2):786-94. PubMed ID: 10623824
[TBL] [Abstract][Full Text] [Related]
12. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
13. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS
Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043
[TBL] [Abstract][Full Text] [Related]
14. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
Kikawada E; Lenda DM; Kelley VR
J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
[TBL] [Abstract][Full Text] [Related]
15. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
Anders HJ; Belemezova E; Eis V; Segerer S; Vielhauer V; Perez de Lema G; Kretzler M; Cohen CD; Frink M; Horuk R; Hudkins KL; Alpers CE; Mampaso F; Schlöndorff D
J Am Soc Nephrol; 2004 Jun; 15(6):1504-13. PubMed ID: 15153561
[TBL] [Abstract][Full Text] [Related]
16. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
17. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
Lenda DM; Stanley ER; Kelley VR
J Immunol; 2004 Oct; 173(7):4744-54. PubMed ID: 15383612
[TBL] [Abstract][Full Text] [Related]
18. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice.
Kadiombo AT; Maeshima A; Kayakabe K; Ikeuchi H; Sakairi T; Kaneko Y; Hiromura K; Nojima Y
Am J Physiol Renal Physiol; 2017 Feb; 312(2):F297-F304. PubMed ID: 27881396
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
Pérez de Lema G; Lucio-Cazaña FJ; Molina A; Luckow B; Schmid H; de Wit C; Moreno-Manzano V; Banas B; Mampaso F; Schlöndorff D
Kidney Int; 2004 Sep; 66(3):1018-28. PubMed ID: 15327395
[TBL] [Abstract][Full Text] [Related]
20. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure.
Bao L; Wang Y; Chang A; Minto AW; Zhou J; Kang H; Haas M; Quigg RJ
J Am Soc Nephrol; 2007 Mar; 18(3):811-22. PubMed ID: 17229915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
